About SapVax

About company

SapVax is advancing discoveries made by researchers from the University of Auckland in New Zealand. Their academic founders have developed a novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines. The Sapvax team is developing a pipeline of products for the treatment of different cancers, with an initial focus on tumors expressing NY-ESO-1.